Comparing Unicycive Therapeutics (NASDAQ:UNCY) and Veru (NASDAQ:VERU)

Veru (NASDAQ:VERU) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

47.2% of Veru shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Veru and Unicycive Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89 million	2.26	-$22.73 million	($0.69)	-3.25
Unicycive Therapeutics	N/A	N/A	-$26.56 million	($1.75)	-2.22

Veru has higher revenue and earnings than Unicycive Therapeutics. Veru is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Veru and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Risk and Volatility

Veru has a beta of -1.21, meaning that its share price is 221% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Veru and Unicycive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Unicycive Therapeutics	1	1	5	0	2.57

Veru presently has a consensus price target of $24.50, indicating a potential upside of 993.75%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 369.15%. Given Veru’s higher probable upside, research analysts plainly believe Veru is more favorable than Unicycive Therapeutics.

Summary

Veru beats Unicycive Therapeutics on 8 of the 12 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.